A recent ESMO update has recommended germline follow-up of tumour-only sequencing including defining the seven ‘most-actionable’ cancer susceptibility genes (BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, RET) in which germline follow up is recommended regardless of primary cancer type [15]. The gene discussed is MLH1; the disease is cancer.